secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0000950170-25-112564
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aficamten superior to metoprolol in MAPLE-HCM Phase 3 trial; primary endpoint met (p<0.0001)
--------------------------------------------------------------------------------

- Least-squares mean pVO2 difference: +2.3 mL/kg/min (95% CI 1.5 to 3.1; p<0.0001) favoring aficamten.
- 51% of aficamten patients improved ≥1 NYHA class vs 26% on metoprolol (p<0.001).
- Aficamten reduced NT-proBNP by 81% vs metoprolol (p<0.0001); 1 patient had LVEF<50%.
- FDA PDUFA target action date for aficamten NDA is December 26, 2025.
- Results published simultaneously in The New England Journal of Medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025112564/0000950170-25-112564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025112564/cytk-20250830.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-112564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer